ArticleBulletin of the World Health Organization2023
Target product profiles: tests for tuberculosis treatment monitoring and optimization.
Article in Bulletin of the World Health Organization, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07018076 (Candidate Clinical Correlate of Prognostic Outcome for TB Study), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Candidate Clinical Correlate of Prognostic Outcome for TB Study
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CXCL9/CXCL10 as biomarkers the monitoring of treatment responses in Pulmonary TB patients: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Host Plasma Protein Biomarkers for Tuberculosis Disease Screening in Febrile Adults in Tanzania.The Journal of infectious diseases · 2026Article
- Blood transcriptomic signatures predict poor outcomes in drug-susceptible pulmonary tuberculosis in Brazil.American journal of respiratory and critical care medicine · 2026Article
- Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development.The Lancet. Infectious diseases · 2026Review
- Article
- The PATHFAST TB LAM Ag assay: a validated protocol for quantitative tuberculosis treatment monitoring.Frontiers in antibiotics · 2026Article
- Simultaneous measurement of 16S-rRNA and pre-16S-rRNA as a strategy to monitor clinical tuberculosis.Frontiers in antibiotics · 2026Article
- Clinical evaluation of the diagnostic performances and treatment monitoring of the new PATHFAST TB LAM Ag assay in sputum specimens of patients with tuberculosis or with nontuberculous mycobacteria pulmonary disease.Journal of clinical microbiology · 2025Article
- Blood transcriptomic signatures predict poor treatment outcomes in drug-susceptible pulmonary TB in Brazil.medRxiv : the preprint server for health sciences · 2025Article
- Tuberculosis Today: Microbial Insights, Epidemiological Trends, and the Role of Molecular Diagnostics.Pathogens (Basel, Switzerland) · 2025Review
- The potential impact, cost and cost-effectiveness of tuberculosis interventions - a modelling exercise.medRxiv : the preprint server for health sciences · 2025Article
- Electro-impedimetric detection of human anti-mycolate antibody biomarkers of TB before, during, and after treatment.Biomarkers in medicine · 2025Observational
- A Prospective Evaluation of a Three-Gene Host Response Signature to Classify Tuberculosis Severity in Children.Journal of the Pediatric Infectious Diseases Society · 2025Article
- Revisiting diagnostics: high priority tuberculosis diagnostic tests that fill an unmet need: what we need and what we do not need.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2025Article
- Neutrophil proteins as potential biomarkers for a sputum-based tuberculosis screening test.Frontiers in immunology · 2025Article
- Evaluation of host-immune biomarker signatures as multiplex qPCR diagnostic assays: a pilot study toward meeting WHO target product profiles for TB diagnosis in India.Frontiers in tuberculosis · 2025Article
- Targeted transcriptomic analyses of tuberculosis treatment response and outcomes in The Gambia.Frontiers in tuberculosis · 2025Article
- Quantification of bactericidal activity using the PATHFAST TB LAM Ag assay during the first 14 days of pulmonary tuberculosis treatment.Frontiers in antibiotics · 2025Article
- Article
- Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles.The Lancet. Microbe · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
The World Health Organization has developed target product profiles containing minimum and optimum targets for key characteristics for tests for tuberculosis treatment monitoring and optimization. Tuberculosis treatment optimization refers to initiating or switching to an effective tuberculosis treatment regimen that results in a high likelihood of a good treatment outcome. The target product profiles also cover tests of cure conducted at the end of treatment. The development of the target product profiles was informed by a stakeholder survey, a cost-effectiveness analysis and a patient-care pathway analysis. Additional feedback from stakeholders was obtained by means of a Delphi-like process, a technical consultation and a call for public comment on a draft document. A scientific development group agreed on the final targets in a consensus meeting. For characteristics rated of highest importance, the document lists: (i) high diagnostic accuracy (sensitivity and specificity); (ii) time to result of optimally ≤ 2 hours and no more than 1 day; (iii) required sample type to be minimally invasive, easily obtainable, such as urine, breath, or capillary blood, or a respiratory sample that goes beyond sputum; (iv) ideally the test could be placed at a peripheral-level health facility without a laboratory; and (v) the test should be affordable to low- and middle-income countries, and allow wide and equitable access and scale-up. Use of these target product profiles should facilitate the development of new tuberculosis treatment monitoring and optimization tests that are accurate and accessible for all people being treated for tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.